Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-03-20
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 508
- Registration Number
- NCT00449605
- Locations
- 🇨🇱
Sanofi-aventis adminsitrative office, Santiago, Chile
🇸🇪Sanofi-Aventis Administrative Office, Bromma, Sweden
Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR)
- Conditions
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT00437554
- Locations
- 🇰🇷
Handok, Seoul, Korea, Republic of
Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-01-26
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 227
- Registration Number
- NCT00427154
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tacoma, Washington, United States
Insulin Glulisine in Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 106
- Registration Number
- NCT00360698
- Locations
- 🇷🇺
Sanofi-Aventis, Moscow, Russian Federation
🇬🇧Sanofi-aventis, Guildford, United Kingdom
Exenatide Versus Glimepiride in Patients With Type 2 Diabetes
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1029
- Registration Number
- NCT00359762
- Locations
- 🇬🇧
Research Site, Wiltshire, United Kingdom
Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT00353691
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 363
- Registration Number
- NCT00343980
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 584
- Registration Number
- NCT00331851
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together
- Conditions
- Interventions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1091
- Registration Number
- NCT00318461
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sunbury on Thames, United Kingdom
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1041
- Registration Number
- NCT00318422
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.